Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner

Stem Cells

Volumn 31, Issue 5, 2013, Pages 870-881

  Gu, Chunyu ^a   Banasavadi Siddegowda, Yeshavanth K ^a   Joshi, Kaushal ^a   Nakamura, Yuko ^a   Kurt, Habibe ^a   Gupta, Snehalata ^a   Nakano, Ichiro ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

c Jun NH(2) terminal kinases; Cancer stem cell; Glioma initiating cell; Neural stem cell; Stress induced kinase

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME; GLIAL FIBRILLARY ACIDIC PROTEIN; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; MESSENGER RNA; PROTEIN KINASE B; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; ENZYME ACTIVATION; GENE SILENCING; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84876567183     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1322     Document Type: Article

References (51)

1. Michotte A, Neyns B, Chaskis C et al. Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta Neurol Belg 2004;104:148-153. (Pubitemid 40277926)
2. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
3. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828. (Pubitemid 37187480)
4. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
5. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
6. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-7848. (Pubitemid 44299144)
7. Gilbertson RJ, Rich JN. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-736. (Pubitemid 47463683)
8. Pollard SM, Yoshikawa K, Clarke ID et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4:568-580.
9. Lathia JD, Gallagher J, Heddleston JM et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010;6:421-432.
10. Hjelmeland AB, Rich JN. Molecular targeting of neural cancer stem cells: TTAGGG, you're it!. Clin Cancer Res 2011;17:3-5.
11. Gil M, Yang Y, Lee Y et al. Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells. Gene 1997;195:295-301. (Pubitemid 27354707)
12. Heyer BS, Warsowe J, Solter D et al. New member of the Snf1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo. Mol Reprod Dev 1997;47:148-156. (Pubitemid 27188223)
13. Hebbard LW, Maurer J, Miller A et al. Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res 2010;70:8863-8873.
14. Rajkumar T, Sabitha K, Vijayalakshmi N et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011;11:80.
15. Nakano I, Masterman-Smith M, Saigusa K et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res 2008;86:48-60.
16. Pickard MR, Green AR, Ellis IO et al. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res 2009;11:R60.
17. Nakano I, Joshi K, Visnyei K et al. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro Oncol 2011;13:622-634.
18. Marie SK, Okamoto OK, Uno M et al. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer 2008;122:807-815.
19. Lin ML, Park JH, Nishidate T et al. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res 2007;9:R17.
20. Badouel C, Chartrain I, Blot J et al. Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit. Exp Cell Res 2010;316:2166-2173.
21. Visnyei K, Onodera H, Damoiseaux R et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 2011;10:1818-1828.
22. Saito R, Nakauchi H, Watanabe S. Serine/threonine kinase, Melk, regulates proliferation and glial differentiation of retinal progenitor cells Cancer Sci 2012;103:42-49.
23. Gray D, Jubb AM, Hogue D et al. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res 2005;65:9751-9761. (Pubitemid 41541452)
24. Seong HA, Gil M, Kim KT et al. Phosphorylation of a novel zinc-finger-like protein, ZPR9, by murine protein serine/threonine kinase 38 (MPK38). Biochem J 2002;361:597-604. (Pubitemid 34177828)
25. Badouel C, Korner R, Frank-Vaillant M et al. M-phase Melk activity is regulated by MPF and MAPK. Cell Cycle 2006;5:883-889. (Pubitemid 44145585)
26. Le Page Y, Chartrain I, Badouel C et al. A functional analysis of MELK in cell division reveals a transition in the mode of cytokinesis during Xenopus development J Cell Sci 2011;124:958-968.
27. Chartrain I, Couturier A, Tassan JP. Cell-cycle-dependent cortical localization of pEg3 protein kinase in Xenopus and human cells. Biol Cell 2006;98:253-263.
28. Fujishita T, Aoki M, Taketo MM. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in ApcDelta716 mice. Gastroenterology 2011;140:1556-1563.
29. Lopez-Bergami P, Kim H, Dewing A et al. c-Jun regulates phosphoinositide-dependent kinase 1 transcription: Implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem 2010;285:903-913.
30. Xu YM, Zhu F, Cho YY et al. Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. Cancer Res 2010;70:3218-3227.
31. Daginakatte GC, Gianino SM, Zhao NW et al. Increased c-Jun-NH2- kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 2008;68:10358-10366.
32. Sancho R, Nateri AS, de Vinuesa AG et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 2009;28:1843-1854.
33. Yoon CH, Kim MJ, Lim EJ et al. C-JUN N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene 2012;31:4655-4666.
34. Nakano I, Paucar AA, Bajpai R et al. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 2005;170:413-427. (Pubitemid 41126941)
35. Jijiwa M, Demir H, Gupta S et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011;6:e24217.
36. Miyazaki T, Pan Y, Joshi K et al. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res 2012;18:1268-1280.
37. Hjelmeland AB, Wu Q, Wickman S et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol 2010;8:e1000319.
38. Cheng L, Wu Q, Huang Z et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 2011;30:800-813.
39. Lathia JD, Gallagher J, Myers JT et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One 2011;6:e24807.
40. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82. (Pubitemid 46054518)
41. Weiss WA. Genetics of brain tumors. Curr Opin Pediatr 2000;12:543-548.
42. Weiss WA, Burns MJ, Hackett C et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63:1589-1595. (Pubitemid 36373648)
43. Di Micco R, Sulli G, Dobreva M et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol 2011;13:292-302.
44. Wang Y, Zhu S, Cloughesy TF et al. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004;23:1283-1290. (Pubitemid 38297183)
45. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024. (Pubitemid 41609094)
46. Lee JC, Vivanco I, Beroukhim R et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006;3:e485.
47. Wang MY, Lu KV, Zhu S et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006;66:7864-7869. (Pubitemid 44299148)
48. Matsuda K, Sato A, Okada M et al. Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci Rep 2012;2:516.
49. Ginsberg D, Oren M, Yaniv M et al. Protein-binding elements in the promoter region of the mouse p53 Gene. Oncogene 1990;5:1285-1290.
50. Schreiber M, Kolbus A, Piu F et al. Control of cell cycle progression by c-jun is p53 dependent. Genes Dev 1999;13:607-619. (Pubitemid 29131884)
51. Baldwin A, Grueneberg DA, Hellner K et al. Kinase requirements in human cells: V. synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci USA 2010;107:12463-12468.